SCHEMBL224065

SCHEMBL224065

CC(=O)N1c2ccc(C(=O)OCc3ccccc3)cc2[C@H](Nc2ccc(N3CCOCC3)cc2)C[C@@H]1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 20/20 0.58
BRD2 P25440 19/20 0.58
BRD3 Q15059 18/20 0.58
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
CYP2D6 P10635 1/20 0.49
TRIM24 O15164 1/20 0.49
TAF1 P21675 1/20 0.49
EP300 Q09472 1/20 0.49
BRDT Q58F21 1/20 0.49
PBRM1 Q86U86 1/20 0.49
TAF1L Q8IZX4 1/20 0.49
CREBBP Q92793 1/20 0.49
BRWD1 Q9NSI6 1/20 0.49
TRIM33 Q9UPN9 1/20 0.49
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL225381 0.89 BRD4 (0.53) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL223901 0.86 BRD4 (0.63) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL223840 0.86 BRD4 (0.63) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL224615 0.86 BRD4 (0.63) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL221357 0.84 BRD4 (0.57) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL5836452 0.84 BRD4 (0.67) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL5836450 0.84 BRD4 (0.67) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL225290 0.83 BRD4 (0.56) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL221798 0.83 BRD4 (0.64) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL224049 0.83 BRD4 (0.64) BRD4BRD2BRD3CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045423-B2 Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient KOWA COMPANY, LTD. (JP) 2015-06-02 US disclosed
US-20140249144-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT KOWA COMPANY, LTD. (JP) 2014-09-04 US disclosed
US-8791090-B2 Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient KOWA COMPANY, LTD. (JP) 2014-07-29 US disclosed
EP-2415764-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT Kowa Company, Ltd. (JP) 2012-02-08 EP disclosed
US-20120004197-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT KOWA COMPANY, LTD. (JP) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249144-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT EPOR, HBG1, HBG2 BRD4 861/4885BRD2 1499/4885BRD3 1556/4885
US-20120004197-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT EPOR, HBG1, HBG2 BRD4 861/4885BRD2 1499/4885BRD3 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.